source
- Sanofi halts development of Nurix's STAT6 degrader programSanofi announced it will stop work on an experimental drug that targets STAT6, a protein involved in immune signaling. The compound, known as SAR448272 and developed in partnership with Nurix, was…
- Sanofi drops Nurix STAT6 degrader program amid molecule-specific concernsSanofi has halted development of an early‑stage STAT6 degrader program that it licensed from Nurix Therapeutics. The decision was announced after the asset entered Phase 1 trials for type 2 inflamm…